KemPharm uses its LATTM platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
|Recent News||More >>|
KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
KemPharm, Inc. Reports Second Quarter 2017 Results
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources|